Article
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Japanese journal of clinical oncology - 1 May 2013
Okano Susumu, Yoshino Takayuki, Fujii Masato, Onozawa Yusuke, Kodaira Takeshi, Fujii Hirofumi, Akimoto Tetsuo, Ishikura Satoshi, Oguchi Masahiko, Zenda Sadamoto, de Blas Barbara, Tahara Makoto, Beier Frank
Abstract excerpt
BACKGROUND: We investigated the tolerability of cetuximab plus radiotherapy in Japanese patients with untreated locally advanced squamous cell carcinoma of the head and neck. METHODS: Patients with epidermal growth factor receptor-expressing locally advanced squamous cell carcinoma of the head and neck received cetuximab (400 mg/m(2) initial dose then 250 mg/m(2) weekly) for 7 weeks plus concomitant boost...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.